Results 1 to 10 of about 4,093 (216)

A CPEB2/ANGPTL3 feedback loop promotes the progression of podocyte injury in nephrotic syndrome [PDF]

Scientific Reports
Podocyte injury is the primary pathology responsible for 70–90% of nephrotic syndrome (NS) in children, a condition closely associated with the aberrant expression of Angiopoietin-like-3 (ANGPTL3). The regulatory mechanism by which ANGPTL3 is upregulated
Xin Zheng, Shuibao Chen, Yizhong Chen, Yuling Wu, Fan Lin, Zihua Yu   +5 more
doaj   +3 more sources

The ANGPTL3-integrin α5 axis drives retinal vascular leakage in diabetic retinopathy [PDF]

Journal of Translational Medicine
Background Breakdown of the blood-retinal barrier (BRB) is a key driver of diabetic retinopathy (DR). While Angiopoietin-like protein 3 (ANGPTL3) is a clinical predictor of DR, its causal role and mechanism in retinal vascular pathology are unknown ...
Jing Ke, Yongsong Xu, Yingjun Zhu, Xiaotong Feng, Haodi Cao, Longyan Yang, Dong Zhao   +6 more
doaj   +3 more sources

ANGPTL3 as therapeutic target

Current Opinion in Lipidology, 2021
Purpose of review Elevated LDL-C and triglycerides are important risk factors for the development of atherosclerotic cardiovascular disease. Although effective therapies for lipid lowering exist, many people do not reach their treatment targets.
Sander Kersten
openalex   +5 more sources

ANGPTL3 gene variants in subjects with familial combined hyperlipidemia [PDF]

Scientific Reports, 2021
Angiopoietin-like 3 (ANGPTL3) plays an important role in lipid metabolism in humans. Loss-of-function variants in ANGPTL3 cause a monogenic disease named familial combined hypolipidemia.
A. M. Bea, E. Franco-Marín, V. Marco-Benedí, E. Jarauta, I. Gracia-Rubio, A. Cenarro, F. Civeira, I. Lamiquiz-Moneo   +7 more
doaj   +2 more sources

The role of ANGPTL3 in controlling lipoprotein metabolism [PDF]

Endocrine, 2016
Angiopoietin-like protein 3 (ANGPTL3) is a secretory protein regulating plasma lipid levels via affecting lipoprotein lipase- and endothelial lipase-mediated hydrolysis of triglycerides and phospholipids. ANGPTL3-deficiency due to loss-of-function mutations in the ANGPTL3 gene causes familial combined hypobetalipoproteinemia (FHBL2, OMIM # 605019), a ...
Matti Jauhiainen
exaly   +4 more sources

Liver-specific in vivo base editing of Angptl3 via AAV delivery efficiently lowers blood lipid levels in mice [PDF]

Cell & Bioscience, 2023
Background Gene editing has emerged as an exciting therapeutic development platform for numerous genetic and nongenetic diseases. Targeting lipid-modulating genes such as angiopoietin-related protein 3 (ANGPTL3) with gene editing offers hope for a ...
Yuanbojiao Zuo, Chen Zhang, Yuan Zhou, Haiwen Li, Weidong Xiao, Roland W. Herzog, Jie Xu, Jifeng Zhang, Y. Eugene Chen, Renzhi Han   +9 more
doaj   +2 more sources

Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia [PDF]

Expert Review of Cardiovascular Therapy, 2020
The prevalence of hypertriglyceridemia (HTG) is increasing. Elevated triglyceride (TG) levels are associated with an increased cardiovascular disease (CVD) risk. Moreover, severe HTG results in an elevated risk of pancreatitis, especially in severe HTG with an up to 350-fold increased risk.
Dallinga-Thie G M, N S Nurmohamed, Erik Stroes   +2 more
exaly   +3 more sources

ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance[S]

Journal of Lipid Research, 2017
Angiopoietin-like (ANGPTL)3 and ANGPTL8 are secreted proteins and inhibitors of LPL-mediated plasma triglyceride (TG) clearance. It is unclear how these two ANGPTL proteins interact to regulate LPL activity.
Jorge F. Haller, Ivory J. Mintah, Lisa M. Shihanian, Panayiotis Stevis, David Buckler, Corey A. Alexa-Braun, Sandra Kleiner, Serena Banfi, Jonathan C. Cohen, Helen H. Hobbs, George D. Yancopoulos, Andrew J. Murphy, Viktoria Gusarova, Jesper Gromada   +13 more
doaj   +2 more sources

ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosis

Journal of Atherosclerosis and Thrombosis
Dyslipidemia is a major risk factor for atherosclerosis and subsequent cardiovascular disease (CVD). Despite conventional treatment with statins, ezetimibe, or PCSK9 inhibitors, there are cases of familial hypercholesterolemia (FH) in which LDL-C levels cannot be sufficiently lowered to the target level, resulting in failure to prevent CVD.
Hirotaka Fukami, Yuichi Oike
openalex   +4 more sources

ANGPTL3 orchestrates hepatic fructose sensing and metabolism

Cell Reports
Fructose metabolism is linked to metabolic dysfunction-associated steatotic liver disease (MASLD), but the regulatory mechanisms governing fructose uptake remain poorly understood. Here, we demonstrate that MASLD livers exhibit increased uptake of fructose-derived carbons compared to healthy livers and identify that the MASLD hepatocyte secretome can ...
Katrin J Svensson, Daniel Fernández, Zeyuan Zhang   +2 more
exaly   +4 more sources